Related Experiment Videos
Glycogen storage disease
1Fiona Elsey Cancer Research Laboratory, University of Ballarat Cancer Research Centre, Ballarat, Victoria, Australia.
Seminars in Hematology
|April 17, 2002
Summary
Glycogen storage disease type 1b (GSD1b) causes neutropenia and recurrent infections. Granulocyte colony-stimulating factor (G-CSF) treatment reduces infections but may cause hypersplenism.
Area of Science:
- Pediatrics
- Hematology
- Genetics
Background:
- Glycogen storage disease (GSD) encompasses rare genetic disorders affecting glucose metabolism.
- GSD type 1b (GSD1b) is distinguished by neutropenia and neutrophil dysfunction, leading to increased infection susceptibility.
- GSD1b arises from a glucose-6-phosphate translocase deficiency, with the genetic defect located on chromosome 11q23.
Purpose of the Study:
- To review the clinical manifestations and treatment of GSD1b.
- To evaluate the efficacy and complications of G-CSF therapy in GSD1b patients.
Main Methods:
- Literature review of GSD1b cases and G-CSF treatment outcomes.
- Analysis of infection incidence, neutrophil function, and adverse events in treated patients.
Main Results:
- GSD1b patients experience recurrent bacterial infections, particularly in the perirectal, ear, skin, and urinary tract areas.
- Recombinant human granulocyte colony-stimulating factor (G-CSF) treatment significantly reduces infection rates and improves quality of life.
- G-CSF appears to correct neutrophil chemotaxis and intracellular killing defects, with no observed cases of myelodysplasia or acute myeloid leukemia.
Conclusions:
- G-CSF is an effective treatment for GSD1b, reducing infection-related morbidity.
- Hypersplenism is a notable complication of G-CSF therapy, potentially necessitating dosage adjustments or splenectomy.